The U.S. multiomics market size was estimated at USD 1.18 billion in 2024 and is projected to reach USD 4.36 billion by 2033, growing at a CAGR of 15.58% from 2025 to 2033. This significant growth is driven by increasing demand for personalized medicine, the integration of artificial intelligence and machine learning in biological data interpretation, and the growing need for comprehensive disease profiling. Moreover, rising investments in research and development by both the government and private sectors and expanding applications in drug discovery, diagnostics, and precision healthcare are expected to propel market growth further over the forecast period.
The evolution of powerful computational tools, cloud-based platforms, and AI-driven analytics has revolutionized how multiomics data is processed, integrated, and interpreted. These technologies allow for the seamless analysis of large-scale, multi-layered datasets, reducing bottlenecks in data handling and accelerating insights. As a result, multiomics workflows are becoming more automated, scalable, and cost-effective, making them increasingly accessible to large pharmaceutical companies and smaller biotech firms, academic institutions, and clinical laboratories. The convergence of these technological advancements is not only expanding the application of multiomics across new disease areas. Still, it is also helping to democratize access to multiomics research, thereby accelerating the market’s growth in the U.S.
This product will be delivered within 2 business days.
Technological Innovations
The rapid pace of technological innovation across omics platforms and analytical tools is the key driver in the U.S. multiomics industry. Breakthroughs in high-throughput sequencing technologies, such as next-generation sequencing (NGS), have dramatically increased the speed and depth of genomic and transcriptomic data generation while reducing the cost per sample. Similarly, advancements in mass spectrometry, chromatography, and imaging technologies have significantly improved the resolution and sensitivity of proteomics and metabolomics studies. These innovations enable researchers to obtain a more detailed and accurate view of complex biological processes, essential for applications in disease research, drug discovery, and precision diagnostics.The evolution of powerful computational tools, cloud-based platforms, and AI-driven analytics has revolutionized how multiomics data is processed, integrated, and interpreted. These technologies allow for the seamless analysis of large-scale, multi-layered datasets, reducing bottlenecks in data handling and accelerating insights. As a result, multiomics workflows are becoming more automated, scalable, and cost-effective, making them increasingly accessible to large pharmaceutical companies and smaller biotech firms, academic institutions, and clinical laboratories. The convergence of these technological advancements is not only expanding the application of multiomics across new disease areas. Still, it is also helping to democratize access to multiomics research, thereby accelerating the market’s growth in the U.S.
U.S. Multiomics Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the U.S. multiomics market report based on product & service, type, platform, application, and end use:Product & Service Outlook (Revenue, USD Million, 2021-2033)
- Products
- Instruments
- Consumables
- Software
- Services
Type Outlook (Revenue, USD Million, 2021-2033)
- Single-cell Multiomics
- Bulk Multiomics
Platform Outlook (Revenue, USD Million, 2021-2033)
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
Application Outlook (Revenue, USD Million, 2021-2033)
- Cell Biology
- Oncology
- Neurology
- Immunology
End Use Outlook (Revenue, USD Million, 2021-2033)
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. U.S. Multiomics Market: Product & Service Business Analysis
Chapter 5. U.S. Multiomics Market: Type Business Analysis
Chapter 6. U.S. Multiomics Market: Platform Business Analysis
Chapter 7. U.S. Multiomics Market: Application Business Analysis
Chapter 8. U.S. Multiomics Market: End Use Business Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this U.S. Multiomics market report include:- BD
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Danaher (Beckman Coulter)
- PerkinElmer, Inc
- Shimadzu Corporation
- Bruker
- QIAGEN
- Agilent Technologies, Inc.
- BGI Genomics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 90 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.18 Billion |
| Forecasted Market Value ( USD | $ 4.36 Billion |
| Compound Annual Growth Rate | 15.5% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
